Drug intelligence / Profile preview

anti-SPP-1

Development stage: Preclinical
Modality: Antibody-Based Therapeutics

Overview

Anti-SPP-1 is a therapeutic agent under investigation for its potential in treating hepatocellular carcinoma (HCC). It targets secreted phosphoprotein 1 (SPP-1), a protein implicated in tumor progression and immune evasion. Preclinical studies suggest that anti-SPP-1 therapy, particularly in combination with anti-CTLA-4 immunotherapy, can significantly inhibit tumor growth. Its mechanism involves modulating the tumor immune microenvironment by suppressing the IL-6/STAT3 signaling pathway, elevating interferon-γ levels, and promoting the infiltration of CD8+ T cells and M1 macrophage polarization, thereby enhancing anti-tumor efficacy.

Targets

SPP1 (Osteopontin)

Beyond the preview

Go deeper on anti-SPP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-SPP-1.

Explore the full profile